Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy

Journal of Viral Hepatitis

Volumn 12, Issue 3, 2005, Pages 251-261

  Tanabe, Y ^a   Nagayama, K ^a   Enomoto, Nobuyuki ^a   Izumi, N ^b   Tazawa, J ^c   Kurosaki, M ^a   Sakamoto, N ^a   Sato, C ^a   Watanabe, M ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c Tsitchiura Kyodo General Hospital   (Japan)

Author keywords

Chronic hepatitis C; Direct sequencing; Hepatitis C virus genotype 2b; NS4A; Sustained biochemical response

Indexed keywords

HLA ANTIGEN CLASS 1; INTERFERON; VIRUS PROTEIN;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS GENOME;

ADULT; AGED; BASE SEQUENCE; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHARMACOGENETICS; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 18344385165     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00511.x     Document Type: Article

References (55)

1. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997; 25: 1527-1538.
2. Choo Q, Kuo G, Weiner A, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
3. Tanaka T, Kato N, Cho M, Sugiyama K, Shimotohno K. Structure of the 3′ terminus of the hepatitis of hepatitis C virus genome. J Virol 1996; 70: 3307-3312.
4. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675.
5. Hoofnagle JK, Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
6. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130.
7. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
8. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001; 33: 1299-1302.
9. Nagayama K, Kurosaki M, Enomoto N et al. Time-related changes in full-length hepatitis C virus sequences and hepatitis activity. Virology 1999; 263: 244-253.
10. Nagayama K, Kurosaki M, Enomoto N, Miyasaka Y, Marumo F, Sato C. Characteristics of hepatitis C viral genome associated with disease progression. Hepatology 2000; 31: 745-750.
11. Nagayama K, Enomoto N, Izumi N et al. Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients. Gut 2001; 48: 830-835.
12. Watanabe H, Enomoto N, Nagayama K et al. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 2001; 183: 1195-1203.
13. He Y, Nakao H, Tan SL et al. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol 2002; 76: 9207-9217.
14. Lan KH, Sheu ML, Hwang SJ et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002; 21: 4801-4811.
15. Arima N, Kao CY, Licht T, Padmanabhan R, Sasaguri Y. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem 2001; 276: 12675-12684.
16. Tan SL, Nakao H, He Y et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA 1999; 96: 5533-5538.
17. Gale M. Jr, Blakely CM, Kwieciszewski B et al. Control of PKR protein kinase by hepatitis C virus nonstructural SA protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208-5218.
18. Zhu N, Ware CF, Lai MM. Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor. Virology 2001; 283: 178-187.
19. Zhu N, Khoshnan A, Schneider R et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998; 72: 3691-3697.
20. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000; 20: 103-126.
21. Forns X, Purcell RH, Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 1999; 7: 402-410.
22. Nakao T, Enomoto N, Takada N, Takada A, Date T. Typing of hepatitis C virus genomes by restriction fragment length polymorphism. J Gen Virol 1991; 72 (Pt 9): 2105-2112.
23. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
24. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-679.
25. Lau JY, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C (erratum appears in Lancet 1993; 342: 504). Lancet 1993; 341: 1501-1404.
26. Smith DB. Evolution of the hypervariable region of hepatitis C virus. J Viral Hepat 1999; 6 (Suppl. 1): 41-46.
27. Higashi Y, Kakumu S, Yoshioka K et al. Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology 1993; 197: 659-668.
28. Koziel MJ, Dudley D, Afdhal N et al. HLA class I restricted cytotoxic T lymphocytes specific for hepatitis C virus: identification of multiple epitopes and characterization of patterns of cytokines release. J Clin Invest 1995; 96: 2311-2315.
29. Cherny A, McHutchison JG, Pasquinelli C et al. Cytotoxic T lymphocyte response to hepatitis C virus derived peptides containing the HLA-A2.1 binding motif. J Clin Invest 1995; 95: 521-530.
30. Shirai M, Arichi T, Nishioka M et al. CTL Responses of HLA-A2.1-transgenic mice specific for hepatits C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol 1995; 154: 2733-2742.
31. Urbani S, Uggeri J, Matsuura Y et al. Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. Hepatology 2001; 33: 1533-1543.
32. Nishiguchi S, Tanaka M, Shiomi S et al. Changes in hypervariable region 1 in patients with chronic hepatitis C of genotype 1b with biochemical response to interferon. Hepatol Res 2002; 23: 237.
33. Pawlotsky JM. Hepatitis C virus infection: virus/host interactions. J Viral Hepat 1998; 5 (Suppl. 1): 3-8.
34. Shimotohno K. Hepatitis C virus and its pathogenesis. Semin Cancer Biol 2000; 10: 233-240.
35. Nasir A, Arora HS, Kaiser HE. Apoptosis and pathogenesis of viral hepatitis C - an update. In Vivo 2000; 14: 297-300.
36. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.
37. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-1974.
38. Mercer DF, Schiller DE, Elliott JF et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933.
39. Failla C, Tomei L, De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 1994; 68: 3753-3760.
40. Lin C, Rice CM. The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. Proc Natl Acad Sci USA 1995; 92: 7622-7626.
41. Lin C, Thomson JA, Rice CN. A central region in the hepatitis C virus NS4A protein. J Virol 1995; 69: 4373-4380.
42. Koziel MJ, Dudley D, Wong JT et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149: 3339-3344.
43. Bartenschlager R, Lohmann V, Wilkinson T, Koch JO. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol 1995; 69: 7519-7528.
44. Penna A, Missale G, Lamonaca V et al. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology 2002; 35: 1225-1236.
45. Renou C, Halfon P, Pol S et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002; 51: 585-590.
46. Yenigun A, Durupinar B. Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J Virol 2002; 76: 1787-1789.
47. Fanning LJ, Levis J, Kenny-Walsh E, Whelton M, O'Sullivan K, Shanahan F. HLA class II genes determine the natural variance of hepatitis C viral load. Hepatology 2001; 33: 224-230.
48. Botarelli P, Brunetto MR, Minutello MA et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104: 580-587.
49. Minutello MA, Pileri P, Unutmaz D et al. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. Exp Med 1993; 178: 17-25.
50. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230.
51. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstractual protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
52. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 1999; 30: 1045-1053.
53. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepatol 2001; 8: 1-18.
54. Tanaka H, Akaza T, Juji T. Report of the Japanese Central Bone Marrow Data Center. Clin Transpl 1996: 139-44.
55. Tokunaga K, Ishikawa Y, Ogawa A et al. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 1997; 46: 199-205.